Latest news and press releases about Anbio Biotechnology Class A Ordinary Shares (NNNN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B).
Price
| Price | $5.58 |
| Market Cap | $245M |
| Exchange | NASDAQ |
| Country | DE |
Valuation Ratios
| P/E Ratio | 28.85 |
| Price / Book | 8.12 |
| EV / EBITDA | 40.75 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 27.49% |
| Return on Invested Capital | 25.46% |
| Return on Assets | 28.07% |
| Gross Margin | 86.10% |
| Operating Margin | 65.20% |
| Net Margin | 72.09% |
Related companies: ANGO · AVNS · CLPT · CMPS · CYH · GOSS · KALV
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NNNN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks